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Abstract	  
 
The long term goal of this research proposal is to further understand the 
transcriptional regulation of the MRP1 promoter in neuroblastoma cells. We are 
primarily focused on two possible mechanisms that might lead to the regulation 
of MRP1 expression: epigenetic modifications, in particular, gene promoter 
methylation and transcription factors namely the regulation by the methyl binding 
protein (MeCP2). Within the 5’ untranslated region of the MRP1 promoter is a 
CpG island that has the potential to be methylated, thus contributing to down 
regulation of MRP1 expression in drug sensitive neuroblastoma cells. Our goal is 
to determine if methylation status of the promoter region and subsequently the 
recruitment of MeCP2 that may play a role in the regulation of MRP1 expression. 
The methylation status of the promoter will be investigated using Methylation 
specific PCR and Bisulfite sequencing; while MeCP2 binding will be examined 
using Chromatin Immunoprecipitation.This project addresses a very important 
question, which is why neuroblastoma patients develop drug resistance. 
Identifying regulatory mechanisms for MRP1 expression can potentially help us 
to determine prognostic factors for drug resistance and further down the road 
lead to the development of better treatment strategies.  
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1.Introduction	  
1.1	  Cancer	  
	  
The yearly death toll of children under the age of 15 worldwide according to World 
Health Organization (WHO) statistics is estimated to be approximately 100,000 deaths as 
a result of childhood cancer. Developing countries, alone hold 94 percent of these 
childhood cancer-related deaths (http://www.who.int/en). 
According to the National Cancer Institute Egypt among the 18,496 new cancer cases 
with confirmed malignancy received between January 2002 and December 2003, 1,937 
(10.5%) were children under the age of 20 years. The most common cancer type was 
leukemia with 643 (33.2%) new cases. Lymphoma was the second most common with 
(18.1%), followed by brain and nervous system tumors accounting for 7.1%, of all 
childhood cancer making it one of the most common early childhood malignancies. 
(Elattar, 2003). 
At the children’s cancer hospital 57357 Egypt, Neuroblastoma is the fourth most 
common type of cancer accounting for 15% of the patients admitted between 2007 and 
2010 (fig 1). In other words the hospital receives around a 100 patients annually (fig 2). 
This of course is only a hospital-based-cancer-registry and in no way represent a true 
picture of the incidence of Neuroblastoma in Egypt. This simply is a small snapshot of a 
segment of the community. Unfortunately Egypt doesn’t have a National Cancer Registry 
of its own, so one can only imagine that the incidence of the disease could be much 
higher than the numbers presented here. Eventually this problem will become a crisis, 
since the global cancer burden is increasing rapidly in developing countries where 
populations continue to expand. 
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Figure 1 Percentage of tumor types in the CCHE. Number of the 
patients received between 2007-2010 showing Neuroblastoma as the 
fourth most common tumor type received by the hospital. 
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Figure 2 Yearly Number of neuroblastoma cases (100 annually) received by CCHE between 
2007-2012.  
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1.2	  Neuroblastoma	  
1.2.1	  Background	  
	  
Neural development starts roughly around the beginning of the third week of embryonic 
development. As the neural folds develop, they enfold and form the neural tube which is 
lined by neuro-ectodermal cells, from which neurons develop.  These neuro-ectodermal 
cells migrate laterally and become neural crest cells. The neural crest cells are pluripotent 
highly migratory cell population that differentiate into a variety of cell types derivatives 
which include the peripheral nervous system, chromaffin cells of the adrenal medulla, 
paraganglia, pericytes, pigment cells and the facial skeleton (Mora & Gerald, 2004). 
Determination of cell fate is governed by a set of genes and correct regulation of these 
genes is essential for normal differentiation into sympathetic neurons, any disregulation 
could trigger the development of a tumor. Neuroblastoma is a disease that arises from a 
malfunction in the neural crest cells and its derivates which encompasses sympathetic 
neurons, sympathetic ganglia and adrenal medulla, and chromaffin cells of adrenal 
medulla and extra-adrenal paraganglia. since it arises from such primitive neuroblasts 
therefore it can occur anywhere within the sympathetic nervous system site of 
presentation (Park, Eggert, & Caron, 2010). 
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Figure 3 Neural crest lineage and possible sites of tumor development. Neural crest cells’ 
derivetives include cartilage and bone cells, cardiac and neurons leading different possible 
sites for the development of tumor cells.  
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1.2.2	  Clinical	  Presentation	  and	  Diagnosis	  
 
Neuroblastoma can arise anywhere along the sympathetic nervous system in nerve tissues 
in the neck, abdomen, chest or pelvis along the migratory pathways of the neural crest 
cells. However 65 % of primary tumors arise in the abdomen with the medulla of the 
adrenal gland being predominant  (Maris, Hogarty, Bagatell, & Cohn, 2007). Presenting 
symptoms and signs wildly vary and are dependent on site of primary tumour in addition 
to the presence or absence of metastatic disease or paraneoplastic syndromes. The first 
symptoms of neuroblastoma are often vague and common such as Fatigue, loss of 
appetite, fever, and joint paint. 
Since the clinical presentations of neuroblastoma as described previously are relatively 
non-specific for neuroblastoma alone therefore most of the cases diagnosed are diagnosed 
by chance. The diagnosis is usually confirmed based on the presence of characteristic 
histolopathological features of tumour tissue or the presence of tumour cells in a bone 
marrow aspirate or biopsy, accompanied by raised concentrations of urinary 
catecholamines (Maris et al., 2007). 
 
1.2.3	  Pathology,	  Staging	  and	  prognosis	  
Neuroblastoma has the appearance of dense nests of undifferentiated cells separated by 
fibrillar bundles. Necrosis, haemorrage and calcification are usually present. Tumor cells 
often form rosettes around a pink fibrillar center. The pathology was reviewed by 
Shimada and his classification is used as a prognostic indicator.  
 Age is taken into account.  
 Several criteria are used :-  
o Tumor is defined as being either "stroma rich" or "stroma poor". 
Stroma rich have more fibrillar material and therefore tend to be 
more mature. 
o Tumor cell differentiation 
19	  
	  
o A mitosis-karyorrhexis index (MKI) is used to evaluate  the nuclear 
morphology . The total number of mitosis and karyorrhectic cells is 
determined among 5000 tumor cells in randomly selected fields 
(less than 100 / 5000 = low and do well, more than 200 / 5000 = 
high). 
With neuroblastoma as with most malignancies, the stage of disease is a very significant 
prognostic factor; children at the first stages of the disease have a better chance than 
children at later stages. Moreover for almost all stages of disease, infants have 
significantly better disease-free survival than older children with equivalent stages of 
disease. Some genetic variables such as MYCN amplification which occurs in 
approximately 20% of primary NB tumors are strongly and consistently associated with 
the presence of metastatic disease and poor prognosis(Shimada et al., 1984). Although 
there has been some improvement in outcome of certain well-defined low risk subsets of 
patients has during the past few decades with a five-year survival rate for children with 
low-risk neuroblastoma being higher than 95%, unfortunately the outcome for children 
with a high-risk clinical phenotype has only improved modestly, with long-term survival 
still less than 40%, Moreover of these high-risk cases a large percentage do not respond 
adequately to chemotherapy and are progressive or refractory. Relapse after completion 
of frontline therapy is not uncommon (Maris et al., 2007) The International 
Neuroblastoma Risk Group (INRG) classification system was developed to establish a 
consensus approach for pretreatment risk stratification (table 1) (Cohn et al., 2009).  
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Table 1 The International Neuroblastoma Risk Group (INRG) classification system. MYCN is a 
very important prognostic factor 
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1.2.4	  Treatment	  	  
 
Deciding the course of treatment to be given to a child with neuroblastoma is based on 
many of the above mentioned factors. For example: 
 Low-risk disease: The patient may only need a simple surgical procedure or 
careful follow-up. 
 Intermediate-risk disease: The patient will probably undergo surgery and four to 
eight months of chemotherapy. Patients with intermediate-risk disease often do 
not need radiation treatments. 
 High-risk disease: almost half of the neuroblastoma patients have high-risk 
disease, either because the tumor has already spread to the bone and bone marrow 
by the time they are found or because test results show high-risk features. With 
high risk patients treatment includes five months of chemotherapy, surgery, 
radiation therapy, high dose chemotherapy followed by stem cell rescue, and 
immunotherapy combined with biological therapy. Although these very intense 
treatments have improved the cure rate of this complex disease, unfortunately, 
high-risk neuroblastoma still has a very high rate of non-responsiveness, or 
relapsing during or after treatment. 
 
 
1.3	  Drug	  resistance	  
 
Two main causes can result in a patient’s cancer failing to respond to a specific therapy: 
individual host factors and specific genetic or epigenetic alterations in the cancer cells. 
Host factors include drug Pharmacokinetics that can range from poor 
absorption/distribution or rapid metabolism or excretion of a drug, resulting in low serum 
levels (Gottesman, 2002). On the other hand cancer cells exhibit specific genetic or 
epigenetic alterations that lead to their resistance. Generally tumors are usually composed 
of mixed populations of cancer cells, some of which are drug-resistant while others are 
drug-sensitive. The administration of chemotherapeutic agents kills off drug-sensitive 
22	  
	  
cells, allowing drug resistant cells to stay behind in a higher proportion (fig.4). As the 
tumor continues in its growth again, chemotherapy may fail because the remaining tumor 
cells are now resistant. This resistance to therapy has been associated with the 
overexpression of two molecular "pumps" in tumor-cells. These pumps which are P-
glycoprotein and the multidrug resistance–associated protein (MRP) belong to the same 
ATP-binding cassette (ABC) superfamily of proteins, which function as energy-
dependent efflux pump. The overexpression of these pumps will thereby lead to active 
expulsion of chemotherapeutic drugs from inside the cells. Giving the chance for tumor 
cells to elude the toxic effects of the drug ("Cancer multidrug resistance," 2000).  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
	  
23	  
	  
	  
1.4	  MRP	  
	  
The MDR phenotype can be conferred solely by overexpression of the MRP gene since it 
was initially cloned from a non-Pgp MDR cell line, H69/AR (Wang & Beck, 1998).One 
of the first members of the MRP family to be characterized was MRP1/ABCC1. MRP1 
has the ability to interact with structurally diverse substrates which are generally bulky, 
nonpolar, weakly amphipathic compounds. However its overexpression in cancer cells 
allows the elimination of a wide range of therapeutic agents as well (fig 5) (Munoz, 
Henderson, Haber, & Norris, 2007). Up regulation of MRP1 was observed in a variety of 
solid tumors including those of the lung, breast and prostate where it has been clearly 
implicated as having a role in their clinical drug resistance (Sullivan et al., 2000). 
Furthermore, MRP1 was found to be frequently overexpressed in a large proportion of 
Non-small cell lung carcinoma (NSCLC) tumors prior to treatment exposure (Wang & 
Beck, 1998). Moreover, several studies have shown that MRP1 expression acts as a 
negative prognostic marker for early-stage breast cancer. Importantly, MRP1 also 
mediates the transport of certain chemotherapeutic drugs, such as methotrexate and 
cyclophosphamide, doxorubicin and many more that are used in regimens for the 
treatment different types of cancers (Munoz, Henderson, Haber, & Norris, 2007). A 
recent study by Hiroaki Goto et al,revealed that neuroblastoma cell lines established after 
exposure to chemotherapy expressed higher MRP1 levels compared to control cell lines 
established before treatment. This study also showed the detectable expression of MRP1 
in primary untreated tumors significantly correlated with a lower probability of survival 
and with other prognostic factors. Thus, the positive expression of MRP1 is likely to be 
one characteristic of high-risk neuroblastoma (Hiroaki Goto, 2000). 
 
1.5	  MRP1	  regulation	  
 
There are two main factors that play a critical role in the regulation of the expression of 
the MRP1 gene: epigenetic and transcription factors. 
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1.5.1	  Epigenetic	  factors	  
	  
Epigenetic modifications are divided into two main categories: DNA methylation and 
histone modifications. DNA methylation occurs where a methyl group is added to 
cytosine to form 5-methylcytosine. This process is catalyzed by enzymes known as DNA 
methyltransferases (DNMT), DNMT accepts a methyl group from the donor molecule S-
adenosyl-L-methionine (SAM), and transfers it to the C-5 of cytosine, forming 5-mC. In 
genomic DNA this process only occurs in cytosines that are followed by a guanine (5' CG 
3') in what is called CpG islands. CpG islands are short interspersed DNA sequences that 
are characteristic for having an elevated C+G base composition. A CpG island is 
therefore defined as a CG-rich region and they are often present in gene promoters. In 
promoters of rapidly transcribed genes is a highly conserved sequence called the TATA 
box which is responsible for transcription initiation. However generally the genes that are 
transcribed at low rates do not contain a TATA box but have a CG-rich stretch instead 
(Juven-Gershon & Kadonaga, 2010). Various cell types have different methylation 
patterns, which contributes to the differences in gene expression in different cell types.for 
instance DNA methylation of a gene's CpG island represses gene expression while 
unmethylation leaves the gene to be freely expressed. As such, abnormal DNA 
methylation in cancer cells leads to aberrant expression patterns (Decock et al., 2012). 
The MRP1 promoter has a highly GC-rich region which does not contain a TATA box 
for directing site-specific transcriptional initiation suggesting alternate recognition 
sequences for transcriptional initiation (Zhu & Center, 1994).  
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Figure 4 methylation mechanism. (A,B) 5-Methylcytosine is produced by the action of the 
DNMT , which catalyses the transfer of a methyl group (CH3) from SAM to the carbon-5 
position of cytosine.(C) methylation silences a gene and prevent its expression. 
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1.5.2	  Transcription	  factors	  
Wild type p53 is a transcription regulatory protein that plays a critical role in both the 
activation and repression of its target genes and is involved in the control of cell growth 
and apoptosis. It is an infamous tumor suppressor and its role is well documented. It is 
usually present at low levels in the cell due to a short half-life of 30 minutes, nevertheless 
it accumulates in response to cellular stress. It binds DNA in a paryicular sequence-
specific manner to activate the transcription of a number of genes, including p21WAF1, 
MDM2 and BAX. WAF1 inhibits G1 cyclin-dependent kinases, blocking cell cycle 
progression from G1 into S phase. MDM2 binds to p53 and blocks its ability to function 
as a transcription factor creating an autoregulatory feedback loop to tightly regulate p53 
levels(fig 7). Tumors with mutant p53 cannot  bind to DNA and up-regulate MDM2 and 
consequently, there is a lack of MDM2 to bind to p53 and target it for ubiquitin-mediated 
degradation, resulting in p53 accumulation inconjunction with this fact P53 inactivation 
is strongly correlated with many  cancers such as neuroblastoma  (Tweddle et al., 2003). 
Additionaly it has been suggested that its transcriptional repression effects result from its 
direct interaction with transcription factors such as Spl. Meanwhile the MRP promoter 
contains three Spl-binding sites (Muredda et al., 2003). It was demonstrated that the 
expression of Spl strongly activates the MRP promoter. Furthermore, it was shown that 
wt p53 can inhibit MRP gene expression by antagonizing the transactivating effect of Spl 
on MRP promoter, suggesting a possible interaction between p53 and Spl. In fact, Spl 
was also shown to be associated with p53 as a heterocomplex (Wang & Beck, 1998).  
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Figure 5 schematic of p53 pathway. In a normal cell p53 is inactivated by its negative 
regulator, mdm2. Upon DNA damage the p53 will dissociate from mdm2 complex. Once 
activated, p53 will induce a cell cycle arrest through p21 to allow cell repair inaddition 
activating BAX and deactivating BCL2 leading to cell  apoptosis to discard the damaged 
cell. 
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1.5.3	  MYCN	  
As discussed before MYCN amplification is one of the most powerful unfavorable 
prognostic factors of neuroblastoma (Brodeur, Seeger, Schwab, Varmus, & Bishop, 
1984) (Maris et al., 2007). Numerous laboratory studies support the hypothesis of mycn 
contributing to the clinically aggressive behavior of high risk NB tumors. MYCN is a 
transcriptional regulator that plays a role in differentiation, cellular proliferation, 
transformation and apoptosis. The MYCN gene encodes a nuclear phosphoprotein that is 
a member of transcription factors having a basic helix–loop–helix/leucine zipper (bHLH-
LZ) motif. For transcriptional activation MYCN dimerizes to MAX, another bHLH-LZ 
protein, at DNA target sequences known as E-boxes found in the promoter region of 
target genes recruiting histone acetyltransferases (HAT) and thereby activating gene 
expression. It has been reported that MYCN can directly bind to the MDM2 promoter up-
regulating it above baseline levels and consequently inhibiting p53-triggered apoptosis 
(fig 8) . This suggests an important pathogenic role for MDM2 in MYCN-driven 
neuroblastoma development (Slack et al., 2005). 
	  
Figure 6 MYCN indirectly regulating P53.MYCN upregulates MDM2 which forms a 
complex with p53 and inhibits its action. 
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Some studies have reported that high levels of MRP1 expression in NB tumors strongly 
correlate with amplification and overexpression of the MYCN oncogene(Bordow et al., 
1994; M Haber, 1999; P Bader, 1999). At the mrp1 promoter region upstream of the start 
site lies three putative E-box elements (Manohar et al., 2004) 
 
	 
	 
	  
	 
Figure 7 Schematic of the MRP1 promoter.The positions of the three putative E-box 
elements in the MRP1 promoter. 
 
 
Increases in the levels of DNA–protein complexes at these sites were clearly evident 
upon overexpression of MYCN. Suggesting that MYCN contributes to the regulation of 
the MRP1 gene by interacting with a putative Ebox element in addition to other cis-acting 
factors in the MRP1 promoter, consequently enhancing levels of MRP1 expression result 
in increased drug resistance (Manohar et al., 2004). 
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Figure 8 MRP1 mode of action.the complex of MYCN and Max bind to MRP1 promoter 
increasing its expression ,thereby increasing the MRP1 protein and subsequently leading to 
increased drug efflux. 
	 
	 
	 
	 
	 
1.5.4	  Mecp2	  
	  
Another possible mechanism in which MYCN can regulate MRP1 expression involves 
the methylation status of the MRP1 promoter. MYCN is known to bind to regions of 
DNA that are hypermethylated through the help of an intermediate methyl binding 
protein (MBD). MeCP2 is one of the MBD proteins which is essential in human brain 
development and has been linked to several cancer types and neurodevelopmental 
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disorders. Previous studies showed that MeCP2 can selectively bind to methylated CpG 
residues, over and above it has been shown to interact with the transcriptional repressor 
SIN3A to recruit histone deacetylases (HDAC) consequently repressing transcription of 
methylated promoters(fig. 11) (Bienvenu & Chelly, 2006). 
However, this classic model of regarding MeCP2 solely as a transcriptional repressor has 
been called into question, a recent study by Charhour et al revealed that a large 
percentage of MeCP2-bound gene promoters were unmethylated and actively transcribed 
also showing  interaction of MeCP2 with the transcriptional activator CREB1 at active 
promoters (fig.11) (Chen, Shin, Thamotharan, & Devaskar, 2013) 
It was also reported by Yasui et al that neuroblastoma cell line SH-SY5Y’s majority of 
MeCP2 binding sites were unmethylated, occurred outside of CpG islands, and that 
downstream genes were actively expressed. 
 
	  
	  
	  
	  
Figure 9 different modes of Mecp2 regulation of genes.Mecp2 can act as a repressor if in 
complex with HDAC and Sin3A on the other hand if in complex with CREB1 it can act as 
an activator. 
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In neuroblastoma Kelly cell line a novel pattern of high frequency co-localization of 
MYCN and MeCP2 was observed. This pattern showed that the majority of 
hypermethylated MYCN sites are also bound by MeCP2 furhtermore that a greater 
number of MYCN/MeCP2 positive sites occur outside of hypermethylated sites (Murphy 
et al., 2011). 
   
 
 
Figure 10 MYCN alone (A), MeCP2 alone (C) and both MYCN and MeCP2 (B); and 
methylated sites bound by MYCN alone (D), MeCP2 alone (F) and both MYCN and 
MeCP2(E). 
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Figure 11 schematic of the MRP1 promoter.this indicates the three E-boxes and sp1 binding 
sites and their positions on the MRP1 promoter. 
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Experimental design 
1. To define the methylation status of the CpG Island within the MRP1 
promoter  
 
 
 
 
 
 
 
Methylation status of  
the MRP1 promoter and 
MRP1 expression 
Real-Time qRT-
PCR 
Demethylation 
treatment 
Real-Time qRT-
PCR 
Bisulfite 
sequencing 
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2. To determine if MeCP2 binds to the MRP1 promoter. 
 
 
 
 
 
 
 
 
 
MRP1 promoter 
binding of MeCP2 
Chromatin 
Immunoprecipitati
on (ChIP) 
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2.Materials	  and	  methods	  
2.1	  Culture	  of	  Neuroblastoma	  Cell	  Lines	  
	  
SK-N-AS, LAN1 and SK-N-Be2c were cultured in RPMI (LONZA,) supplemented with 
10% (v/v) Fetal Bovine Serum (LONZA) and 1% (v/v) Penicillin-Streptomycin-
Amphotericin B (LONZA). UKFNB3, UKFNB3 DOX and UKFNB4 were cultured in 
IMDM (LONZA,) supplemented with 10% (v/v) Fetal Bovine Serum (LONZA) and 1% 
(v/v) Penicillin-Streptomycin-Amphotericin B (LONZA). All human tumor-derived cell 
lines were grown in 37°C with 5% CO2. Cell lines were a generous donation from Dr. 
Jaume Mora. 
 
Table	  2	  cell	  lines	  
Cell Line  
P53  
Status  
N-Myc  
Drug  
Sensitivity  
SK-N-AS  Wild Type  Non Amplified  Sensitive  
SK-N-BE(2)-C  
Mutant  
C135F  
Overexpressed  Resistant  
LAN-1  Mutant  Overexpressed  Resistant  
UKF-NB-3  Wild Type  Overexpressed  Sensitive  
UKF-NB-3 Dox  Wild Type  NA  Resistant  
UKF-NB-4  
Mutant  
C175F  
Overexpressed  Sensitive  
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2.2	  Extraction	  of	  Genomic	  DNA	  
 
DNA was extracted using GeneJET Genomic DNA Purification Kit #K0721(Thermo 
Scientific,) according to the manufacturer's protocol. Cells at 80% confluence were taken 
and the adherent cells were detached using Trypsin (Lonza). Cells were transferred to a 
microcentrifuge tube and pelleted by centrifugation for 5 minutes at 1300 rpm x g . Cells 
were then resuspended in in 200 µl of PBS (Lonza) and 200 µl of Lysis Solution and 20 
µl of Proteinase K solution were added to the cell pellet followed by vortexing to obtain a 
uniform suspension. The samples were incubated at 56°C while vortexing occasionally 
for 10 min until the cells were completely lysed and 400 µl of 50% ethanol was added to 
the lysed cells. Afterwards the lysates were transferred to  GeneJET Genomic DNA 
Purification Columns inserted in collection tubes and centrifuged for 1 min at 6000 x g 
then the GeneJET Genomic DNA Purification Columns were placed into a new 2 ml 
collection tube followed by the addition of 500 µl of Wash Buffer I and Centrifuged for 1 
min at 8000 x g. this step was repeated again using wash buffer II and Centrifuged for 3 
min at maximum speed (≥12000 x g).finally 50µl of Elution Buffer was added to the 
center of the GeneJET Genomic DNA Purification Column membranes to elute genomic 
DNA, Incubated for 2 min at room temperature and centrifuged for 1 min at 8000 x g. 
The DNA was then stored at -80°c.DNA concentration was assessed using UV 
spectrophotometer (Beckman Coulter DU ® 700 Series).  By diluting 2 µl DNA in 98 µl 
of distilled water and measuring at λ260 and λ280 and using the following formula to 
assess the concentration: 
 
 
 
 
 
 
 
DNA concentration (µg/µl) = [OD260 x (dilution factor) x 50]/1000 
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2.2.1	  Bisulfite	  Treatment	  of	  DNA	  
	  
Bisulfite DNA modification was carried out using EpiTect Bisulfite DNA conversion kit 
(Qiagen) according to the manufacturer's protocol. The required number of aliquots of 
Bisulfite Mix wwew dissolved by adding 800 µl RNase-free water to each aliquot and 
vortexed until the Bisulfite Mix was completely dissolved. The bisulfite reactions were 
prepared in PCR tubes as follows: 
Table	  3	  Bisulfite reaction components 
DNA solution 
 
2ng 
RNase-free water 
 
Variable 
Bisulfite Mix 
 
85 µl 
DNA Protect Buffer 
 
35 µl 
Total volume 
 
140 µl 
 
The bisulfite DNA conversion was performed using a thermal cycler with the following 
conditions: 
Denaturation 5 min 95°C, 
Incubation 25 min 60°C, 
Denaturation 5 min 95°C, 
Incubation 85 min 60°C 
Denaturation 5 min 95°C, 
Incubation 175 min 60°C  
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Finally Hold Indefinite at 20°C. 
2.2.2	  Cleanup	  of	  bisulfite	  converted	  DNA	  
 
Once the bisulfite conversion was complete, the PCR tubes containing the bisulfite 
reactions were briefly centrifuge, and then transferred to clean 1.5 ml microcentrifuge 
tubes. 560 µl freshly prepared Buffer BL containing 10 µg/ml carrier RNA was added to 
each sample. The solutions were mixed by vortexing and then centrifuged briefly. The 
entire mixture was transferred from the tubes into corresponding EpiTect spin columns. 
Then the spin columns were centrifuged at maximum speed for 1 min and the flow-
through discarded. 500 µl Buffer BW (wash buffer) was added to each spin column and 
centrifuged at maximum speed for 1 min and the flow-through was discarded. 500 µl 
Buffer BD (desulfonation buffer) is then added to each spin column and incubated for 15 
min at room temperature (15–25°C) followed by centrifugation of the spin columns at 
maximum speed for 1 min and the flow-through discarded. To each spin column 500 µl 
Buffer BW was added and centrifuged at maximum speed for 1 min. The flow-through 
was then discarded. This step was repeated twice followed by centrifugation at maximum 
speed for 1 min to remove any residual liquid. Finally 20 µl Buffer EB was added onto 
the center of each membrane to elute the DNA and the columns centrifuged for 1 min at 
approximately 15,000 x g (12,000 rpm.). 
 
2.2.3	  Amplification	  of	  Methylated	  and	  Unmethylated	  MRP1promoter	  
  
Bisulfite-treated DNA was amplìfied using primers specific for the methylated and 
unmethylated MRP1 promoter sequence. 
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Primers were designed using Methyl primer express® software v1.0 (Applied 
Biosystems)  
Table	  4	  MSP primers	  
Primer 
Sequence 
MRP1 F FWD                                  
5' TTCGGAAGGCGAGTTAAC 3' 
MRP1 F REV 
5' CGTAAACAACCGAACCAAC 3' 
MRP1 G FWD 
5' GTTTTTGGAAGGTGAGTTAAT 3' 
MRP1 G REV 
5' AACATAAACAACCAAACCAACC 3' 
2.2.4	  Methylation	  specific	  Pcr	  
The PCR reaction was carried out using Qiagen Hot Start DNA Polymerase (Qiagen) in a 
total reaction volume of 100 µl as follows: 
Figure 12 schematic of primers designed for MSP 
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Table	  5	  MSP reaction components	  
PCR Buffer (10x) 
 
10 µl 
Qsolution (5x) 
 
20µl 
dNTP mix (10 mM of each) 
 
2 µl 
Forward primer 
1 µl 
 
Reverse primer 
 
1 µl 
HotStarTaq enzyme 
 
0.5 µl 
Template DNA 
 
5 µl 
RNase-free water 
 
61 µl 
Total volume 
 
100 µl 
 
The PCR reaction was carried out following conditions: 
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2.2.5	  Bisulfite	  sequencing	  
Bisulfite-treated DNA was amplìfied using primers specific for sequencing. 
 
Primers were designed using Methyl primer express® software v1.0 (Applied 
Biosystems)  
Table	  6	  bisulfite	  sequencing	  primers	  
Primer 
Sequence 
 
MRP1 A FWD 
5' GTTAGGTGATTTTGGGTAGAGG 3' 
MRP1 A REV 
5' CCCAAATCCTCCAAAACTTA 3' 
2.2.6	  PCR	  
PCR was carried out as illustrated earlier. 
2.2.7	  Size	  selection	  using	  1%	  agarose	  gel	  
100 µl of PCR products were loaded onto 1% agarose gels stained with ethidium 
bromide. The gel was visualized using Gel Documentation Systems.DNA was extracted 
using GeneJET Gel Extraction  Kit #K0691(Thermo Scientific) according to 
manufacturer's protocol.Gel slice containing the DNA fragment was excised using a 
clean scalpeland placed into a pre-weighed 15 ml tube. Binding Buffer was added 1:1 
Figure 13 schematic of Bisulfite sequencing primers 
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volume to the gel slices (volume: weight). The gel mixtures were incubated at 50-60°C 
for 10 min until the gel slices were completely dissolved. The solubilized gel solutions 
were then transferred to the GeneJET purification columns and centrifuged for 1 min. 
The flow-through was discarded and the columns were placed back into the same 
collection tubes. 700 µl of Wash Buffer was added to the GeneJET purification columns 
and centrifuged for 1 min and an additional 1 min to completely remove residual wash 
buffer. Finally the GeneJET purification columns were placed into clean 1.5 ml 
microcentrifuge tubes and 50 µl of Elution Buffer was added to the center of the 
purification column membranes. After centrifugation for 1 min the purified DNA was 
stored at-80°c. 
2.2.8	  Tailing	  reaction	  
 
Tailing reaction was carried out with a non-proof reading enzyme Taq DNA Polymerase 
Recombinant (Thermo Scientific) as follows:  
 
Table	  7	  tailing reaction components	  
PCR product 
 
20 µl 
Taq Buffer with KCl (10X) 
 
5 µl 
25 mM MgCl2 
 
3 µl 
Taq polymerase 
 
1.25 µl 
dATP (10mmol) 
 
1 µl 
Water 
 
19.75 µl 
Total volume 
 
50 µl 
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The reaction mixture was incubated at 70 ºC for 20 min. 
 
2.2.9	  Purification	  	  
 
Purification was carried out using PCR Purification Kit (Thermo Scientific) according to 
manufacturer's protocol. To the tailing reaction 1:1 volume of Binding Buffer was added 
and the mixture transferred to the GeneJET™ purification columns. The columns were 
then centrifuged for 1 min and the flow-through discarded.100 µl of Binding Buffer was 
added to the GeneJET™ purification columns and centrifuged for 1 min. Again the flow-
through was discarded. The GeneJET purification columns were transferred into a clean 
1.5 ml microcentrifuge tube. And 25 µl of Elution Buffer added to the center of the 
purification column membranes centrifuged for 1 min. 
 
2.2.10	  Cloning	  of	  PCR	  products	  generated	  by	  primer	  A	  
 
PCR products were cloned using InsTAclone PCR Cloning Kit (thermo Scientific). The 
ligation reactions were set up as follows Vector pTZ57R/T (0.17 pmol ends) 3 µl, 5X 
Ligation Buffer 6 µl, purified pcr 20 µl,T4 DNA Ligase 1 µl giving a total volume of 30 
µl. Then vortexed and centrifuged briefly. The ligation mixtures were then incubated at 
room temperature (22°C) for 1 hour. TaKaRa E.coli JM109 Competent Cells (TaKaRa) 
were thawed in an ice bath just before use. Cells were gently mixed and 50 µl was added 
to 2.5 µl of each ligation mixture directly for bacterial transformation and kept in the ice 
bath for 30 min. After the ice bath cells were incubated for 45 sec. at 42｡C and quickly 
returned to the ice bath for 1-2 min. 500 µl SOC medium (pre-incubated at 37｡C) was 
added to the competent cells and incubated by shaking (160-225 rpm) for 1 hour at 37｡C 
then plated on selective media containing Ampicillin (50 mg/ml) ,X-Gal  (20 mg/ml) and 
IPTG 100 mM.  
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2.2.11	  Plasmid	  extraction	  
 
Miniprep was carried out using GeneJET Plasmid Miniprep Kit (Thermo Scientific) 
according to manufacturer's recommendation. Positive colonies were picked from a 
freshly streaked selective plate to inoculate each one in 5 ml of LB medium 
supplemented with the ampicillin antibiotic (50 mg/ml). The cultures were incubated over 
night at 37°C while shaking at 200-250 rpm. The bacterial cultures were harvested by 
centrifugation at 8000 rpm (6800 x g) in a microcentrifuge for 2 min at room 
temperature. The pelleted cells were then resuspended in 250 µl of the Resuspension 
Solution and transferred to microcentrifuge tubes. To the cell suspensions 250 µl of the 
Lysis Solution was added and mixed thoroughly by inverting the tubes 4-6 times until the 
solution became viscous and slightly clear. The tubes were centrifuged for 5 min to pellet 
cell debris and chromosomal DNA. The supernatants were transferred to the GeneJET 
spin columns by pipetting. the spin columns were then centrifuged for 1 min and the 
flow-through discarded. 500 µl of the Wash Solution was added to the GeneJET spin 
columns and centrifuged for 30-60 seconds. This step was repeated twice. And 25 µl of 
Elution Buffer added to the center of the purification column membranes centrifuged for 
1 min to elute the plasmid DNA.  
 
2.2.12	  Colony	  PCR	  identification	  
 
DNA was amplified using M13/pUC Sequencing Primers (Thermo Scientific)  using 
Dream Taq (Thermo Scientific) in a total reaction volume of 50 µl as follows: 
 
Table	  8	  colony PCR reaction components	  
DreamTaq DNA Polymerase Master Mix 
 
25 µL 
Forward primer 
 
1 µL 
Reverse primer 
 
1 µL 
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Template DNA 
 
5 µL 
Water nuclease-free 
 
18 µL 
Total volume 
 
50 µl 
 
2.2.13	  DNA	  Sequencing	  
  
Sequencing was done in our lab using the ABI 3730xl DNA Analyzer following the 
BigDye® Terminator v1.1 Cycle Sequencing protocol. Each of the plasmids was 
sequenced using the M13/pUC Sequencing Primers. 
 
2.3	  Extraction	  of	  Total	  RNA	  
Total RNA isolation was performed using TRizol Reagent (Invitrogen,) according to 
manufacturer's protocol. Cells were cultured in 6 well plates. 1ml of TRIzol reagent 
(invitrogen) was added to each well after the removal of the culture media and leaving 
behind the attached cells. Followed by incubation for 2 min at room temperature.  Cells 
were lysed in well by pipetting up and down several times. Lysed cells were collected 
and transferred to a microcentrifuge tube on ice. 0.2 mL of chloroform was added per 1 
mL of TRIzol Reagent and tubes were shaked vigorously by hand for 15 seconds 
followed by an incubation period of 2–3 minutes on ice. Tubes were centrifuged at 
12,000 × g for 15 minutes at 4°C.  The aqueous phase of the sample was removed by 
angling the tube at 45° and pipetting the solution out avoiding drawing any of the 
interphase or organic layer into the pipette and placed in new tube.	   0.5 mL of 100% 
isopropanol was added to the aqueous phase, per 1 mL of TRIzol Reagent and incubated 
on ice for 10 minutes and centrifuged at 12,000 × g for 10 minutes at 4°C. finally the 
supernatant was removed from the tube, leaving only the RNA pellet and washed with 1 
mL of 75% ethanol per 1 mL of TRIzol® Reagent.to discard the wash tubes were 
centrifuged at 7500 × g for 5 minutes at 4°C. The RNA pellet was air dried for 5–10 
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minutes and the RNA pellet was resuspended in15 µl RNase-free water. RNA 
concentration was assessed using UV spectrophotometer (Beckman Coulter DU ® 700 
Series).  By diluting 2 µl RNA in 98 µl of distilled water and measuring at λ260 and λ280 
and using the following formula to assess the concentration: 
 
 
 
The integrity of RNA was checked by agarose gel electrophoresis. 
 
 
2.3.1	  Expression	  of	  MRP1	  and	  MDR1	  mRNA	  by	  RT-­‐PCR	  
 
cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit #K1621. 1µg 
of RNA , 1µl of oligo (dT)18 primer and nuclease-free water was added into a sterile, 
nuclease-free tube on ice to reach a final volume of 12 µl. the tube was centrifuged 
briefly and incubated at 65°C for 5 min. After centrifugation the tube was placed back on 
ice and the following reagents were added in this order 4µl 5X Reaction Buffer, 1 µl 
RiboLock RNase Inhibitor (20 u/µl), 2 µl 10 mM dNTP Mix and finally 1 µl RevertAid 
M-MuLV Reverse Transcriptase (200 u/µl) giving a total volume of 20 µl and incubated 
for 60 min at 42°C followed by heating at 70°C for 5 min to terminate the reaction. 10 µl 
of PCR products were loaded onto 2 %  agarose gels stained with ethidium bromide. The 
gel was visualized using Gel Documentation Systems. RT-PCR was then carried out 
using Dream Taq (Thermo Scientific) in a total reaction volume of 50 µl as follows: 
 
Table	  9	  RT-­‐ PCR reaction components	  
DreamTaq DNA Polymerase Master Mix 
 
25 µL 
Forward primer 
 
1 µL 
Reverse primer 1 µL 
 
DNA concentration (µg/µl) = [OD260 x (dilution factor) x 40]/1000 
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Template DNA 
 
3 µL 
Water nuclease-free 
 
18 µL 
Total volume 
 
50 µl 
 
cDNA was amplified using the following primers 
 
Table	  10	  MRP1	  expression	  primers	  
MRP 1 FWD CTGGGCTTATTTCGGATCAA 
MRP 1 REV TGAATGGGTCCAGGTTCATT 
 
2.3.2	  Demethylation	  Treatment	  of	  Cell	  Lines	  	  
 
The protocol was adapted from (El-Osta, Kantharidis, Zalcberg, & Wolffe, 2002)Cells 
were split to low density 24 h before drug treatment. Cells were treated with 5-Aza-2′-
deoxycytidine (5-AZA-dc) for approximately 3 days. 5-AZA-DC was added at 1 µM for 
32 h followed by two additional doses for 16 h, respectively. 
 
2.3.3	  Real-­‐Time	  Quantitative	  PCR	  
 
Real-Time Quantitative PCR was performed using Applied Biosystems 7500 real-time 
PCR machine. TaqMan probes for (MRP1) (Applied Biosystems) were used in a 20 µl 
reaction as follows: 
 
Table	  11	  Realtime PCR reaction components	  
20X TaqMan gene expression assay 1µl 
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(MRP1)  
2X TaqMan gene expression Master Mix 
10µl 
 
cDNA template 
50 ng 
 
RNase-free water 
5µl 
 
Total volume 
20µl 
 
 
TaqMan probes for 18S ribosomal RNA (Applied Biosystem) were used as control in a 
50 µl reaction as follows: 
Table	  12 Realtime PCR reaction components 2	  
TaqMan® Universal PCR Master Mix 
25µl 
 
10 µM Ribosomal RNA Forward 
Primer 
0.25 µl 
10 µM Ribosomal RNA Reverse 
Primer 
0.25 µl 
40 µM Ribosomal RNA Probe (VIC.) 
0.25 µl 
 
cDNA template 
50 ng 
 
RNase-free water 
Variable 
 
Total volume 
50 µl 
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Table	  13 Realtime PCR reaction conditions	  
 
The experiments were repeated 3 times and the SD was calculated. 
For each sample, the MRP1 CT value was normalized using the following formula: 
 
 
 
 
 
To determine relative expression levels the following formulas were used: 
 
 
 
	  
	  
 
 
 
 
 
 
 
 
 
 
 
∆CT = CTMRP1- CT18S 
	  
 
∆∆CT = ∆CT (reference) - ∆CT (sample) 
	  
 
∆∆CT = ∆CT (treated) - ∆CT (un-treated) 
	  
 
Fold difference = 2^–ΔΔCt 
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2.4	  Chromatin	  Immunoprecipitation	  
 
Chromatin Immunoprecipitation was carried out using EpiXplore kit (clontech). Cells 
were fixed by adding 10 ml of 1% formaldehyde in culture medium; the plate was 
incubated for 10 min at room temperature. Then 2.1 ml quenching solution was added to 
final concentration of 347 mM and incubated for 5 min at room temperature. The solution 
was removed and plate was washed with 1X PBS. Cells were collected. Afterwards cells 
were centrifuged at 400 x g for 3 min at 4°C. Supernatant was discarded and cells were 
resuspended in 1 ml of cytoplasmic lysis buffer with 1 µl of ProteoGuard™ Protease 
Inhibitor Cocktail. Then the tubes were left to sit on ice for 10 min and gently vortexed 
every 5 minutes. After incubation on ice cells were centrifuged at 2,400 × g for 10 min at 
4°C to pellet nuclei which were resuspended in 300 µl of wash buffer. By using a 
Branson digital sonifier model 150, output power was set up to number 3 and DNA was 
carefully sheared to 5 cycles with 10 seconds on and 10 seconds off. After that the 
samples were centrifuged at 15,000 × g for 10 min at 4°C and supernatant was collected. 
For magnetic beads preparation 200 µl of magnetic beads were washed 2 times with 200 
µl of wash buffer and resuspend  in 20 µl of wash buffer. Immunoprecipitation reaction 
was set up as follows: 
 
Table	  14 ChIP reaction components	  
Magnetic Beads in RB1 
 
20 µl 
Sheared Chromatin 
 
25 µl 
ProteoGuard Protease Inhibitor Cocktail 
 
2 µl 
10X Easy Dilution Buffer 
 
20 µl 
Antibody (Mecp2) 
 
8 µl 
RB1 125 µl 
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Total Volume 
 
200 µl 
 
 
 Using a magnetic stand unbound chromatin was removed followed by the washing of 
beads with 800 µl of wash buffer, 800 µl of wash buffer 2 and 800 µl of wash buffer 3 
respectively. Then 100 µl of 10 % DNA Purifying Slurry was added to the beads and 
incubated at 95°C for 15 min to reverse crosslink. Followed by the addition of 1 µl of 20 
mg/ml Proteinase K and incubated at 60°C for an additional 15 min. Using a magnetic 
stand supernatant was collected into new tube.  
 
2.4.1	  PCR	  
 
Primers were designed using  
 
Table 15 ChIP primers 
Primer  
 
Sequence  
Forward primer 
 
5' CTGGTGACGGATACTGTCCTTA 3' 
Reverse primer 
 
5' TGATCGGGCCCGGTTGCTAG 3' 
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Figure	  14	  Schematic	  of	  ChIP	  PCR	  primers 
Pcr reaction was carried out using Phire Hot Start DNA Polymerase (Fermentas) 
Table 16 ChIP PCR reaction components	  
5x PhireReaction Buffer 10 µl 
2 mM dNTPs 5 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
Phire Hot Start DNA Polymerase 1 µl 
Chromatin 25 µl 
H2O 7 µl 
Total volume 50 µl 
54	  
	  
3.	  Results	  	  
 
 
3.1	  Methylation	  Analyses	  of	  the	  MRP1	  promoter	  in	  neuroblastoma	  cell	  
Lines.	  	  
 
Methylation specific PCR was utilized to study the methylation pattern of the CGs 
present in the CpG island within the MRP1 promoter and its relation to the gene’s 
expression in neuroblastoma cell lines. Methylation Specific PCR (MSP) is a bisulfite 
conversion based PCR technique for the study of DNA CpG methylation. For the MSP 
experiment, two pairs of primers were designed with one pair specific for methylated 
DNA (M) and the other for unmethylated DNA (U). To achieve discrimination for 
methylated and unmethylated DNA, CpG sites were included in each primer sequence. 
Then, two PCR reactions were performed using M primer pair and U primer pair. 
Successful amplification from M pair and U pair indicated methylation and 
unmethylation respectively.  MSP was performed on 6 neuroblastoma cell lines 3 drug 
sensitive: (SK-N-AS, UKF-NB-3, UKF-NB-4) and 3 drug resistant: (SK-N-BE(2)-C , 
LAN1, UKF-NB-3-DOX). As shown in (figure16.A,B) all 6 cell lines did not show any 
methylation. However we observed that the bands generated by the unmethylated primers 
showed varying intensities on the gel. This might indicate that the percentage of 
unmethylated CGs differ between cell lines leading to lower annealing of the primers 
giving a weak PCR Product. Subsequently there might be a low percentage of undetected 
methylated CGs. Therefore bisulfite sequencing was necessary to further define and 
expand the analysis of the CpG Island. 
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Figure 15 MSP analysis performed on the 6 cell lines. (A,B) show the cell lines SK-N-AS,
LAN1, SK-N-BE(2)-C, UKF-NB-4, UKF-NB-3 and UKF-NB-3-DOX amplified with primer 
(F and G) showing this region to be unmethylated. 
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3.2	  	  Bisulfite	  Sequencing	  	  
 
A more in-depth look at the promoter region was necessary. Bisulfite genomic 
sequencing is regarded as a gold-standard technology for detection of DNA methylation. 
It provides a qualitative, quantitative and efficient approach to identify methylation at 
single base-pair resolution. We designed primers outside of the CpG region of interest 
thereby amplifyimg the target regardless of the methylation state of the internal sequence. 
Bisulfite sequencing provides an inherently more accurate assessment of the methylation 
state of a sample compared to PCR primers that select for presupposed fully methylated 
or fully unmethylated complementary sequences as seen in the previous figure with MSP. 
Following PCR the amplified product was then sequenced. A 301bp region of the 
promoter, 614bp upstream of the ATG start site was sequenced in the six cell lines. 
The promoter region was amplified using primer A (Fig 18) and cloned for subsequent 
sequencing. Primary screening was carried out as shown (Fig 19) using the blue/white 
method. Subsequently positive white colonies were picked and grown on LB broth and 
the plasmids extracted. 
 
Secondary screening was performed on the potential positive clones. Colony PCR was 
conducted using M13/pUC Reverse sequencing Primer (-26), 17-mer and M13/pUC 
sequencing primer (-20), 17-mer as shown in (figure 20). Thereby giving a PCR product 
of 401bp as shown in (figure 21) accounting for both the length of the insert and the 
vector. 
 
 
 
 
 
 
 
 
57	  
	  
Figure 16 PCR products of primer A in the 6 cell lines. all pcr products shown with a length 
of 301bp. 
Figure 17 bacterial clones. Agar plate showing positive 
(white) and negative (blue) colonies 
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Figure 18 schematic of PUC cloning vector.  the regions where the PCR primers anneal 
adding a 100bp to the insert length. 
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Figure 19 Colony PCR. Secondary screening of the clones showing positive bands 
approximately 410bp 
401bp	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3.2.1Sequencing	  primer	  A	  
 
Extracted plasmids from single positive clones were sequenced using M13/pUC Reverse 
sequencing Primer (-26), 17-mer and the sequences were analyzed using BiQ Analyzer 
(max planck institute informatik). 
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Figure 20 lollipop diagram for UKFNB3 cell line.showing the methylation pattern of the 
CGs and their methylation in the sequenced region. 
	  
Figure 21 methylation percentage for UKFNB3 cell line.showing the methylation pattern of 
the CGs and their percentage in the sequenced region. 
62	  
	  
Figure 22 lollipop diagram for UKFNB3-DOX cell line. showing the methylation pattern of 
the CGs and their methylation in the sequenced region. 
	  
Figure 23 methylation percentage for UKFNB3-Dox cell line.showing the methylation 
pattern of the CGs and their percentage in the sequenced region. 
63	  
	  
Figure 24  lollipop diagram for UKFNB4 cell line.showing the methylation pattern of the 
CGs and their methylation in the sequenced region. 
	  
Figure 25 methylation percentage for UKFNB4 cell line.showing the methylation pattern of 
the CGs and their percentage in the sequenced region. 
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Figure 26 lollipop diagram for SKNAS cell line.showing the methylation pattern of the CGs 
and their methylation in the sequenced region. 
	  
Figure 27 methylation percentage for SKNAS cell line.showing the methylation pattern of 
the CGs and their percentage in the sequenced region. 
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Figure 28 lollipop diagram for SKNBe2c cell line.showing the methylation pattern of the 
CGs and their methylation in the sequenced region. 
	  
Figure 29 methylation percentage for SKNBe2c cell line.showing the methylation pattern of 
the CGs and their percentage in the sequenced region. 
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Figure 30  lollipop diagram for LAN1 cell line.showing the methylation pattern of the CGs 
and their methylation in the sequenced region. 
	  
Figure 31 methylation percentage for LAN1 cell line.showing the methylation pattern of the 
CGs and their percentage in the sequenced region. 
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3.2	  MRP1	  expression	  
 
3.2.1	  Reverse	  transcription-­‐polymerase	  chain	  reaction	  
 
To correlate the methylation status with MRP1 transcription, an RT-PCR analysis which 
is a sensitive method for the detection of mRNA expression levels was performed using 
primer MRP1 1 to determine the expression of MRP1 gene in the neuroblastoma cell 
lines. MRP1 was expressed in all of the 6 cell lines (Fig 22.A,B).  
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Figure 32 Expression of MRP1. (A) shows SK-N-Be2c,LAN1 and SK-N-AS,(B) shows UKF-
NB4 UKF-NB3 and UKF-NB3-DOX 
69	  
	  
3.2.2	  Real	  Time-­‐PCR	  
 
To further assess the level of MRP1 gene expression in the 6 cell lines, Real Time-PCR 
was performed on each. Real Time PCR is quantitative PCR method for the 
determination of copy number of PCR templates we used a probe-based real-time PCR 
(TaqMan probes). This method allows the sensitive, specific and reproducible 
quantitation of nucleic acids. The results were compared to the UKF-NB3 cell line, which 
had the lowest MRP1 expression. The experiment was performed three times. The mean, 
standard deviation, and t-test were then calculated for each cell line (Table 12). The 
results show three cell lines showing high MRP1 expression, SKN-Be2c, LAN1, SKNAS 
with 8, 5, 4 fold change respectively (fig 23), the highest being SKN-Be2c which is a 
drug resistant cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
.  
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Table	  17	  Real-­‐Time	  PCR	  results.	  Table	  showing	  results,	  average	  standard	  deviation	  and	  t	  
test	  of	  the	  three	  experiments	  	  
 
	  
	  
	  
 
 
 
 
 
 
 
 
 
Cell Name EXP 1 EXP 2 EXP 3    
 
MRP1 2^-
(ddct) 
MRP1 2^-
(ddct) 
MRP1 2^-
(ddct) average st dev t test 
Ukfnb4 1.2397	   0.694	   0.95	   0.961233	   0.273023	   0.82867	  
Ukfnb3 
dox 1.897	   0.658	   2.006	   1.520333	   0.748789	   0.351876	  
Ukfnb3 1	   1	   1	   1	   0	   	  	  
Sknbe2c 10.913	   7.621	   9.063	   9.199	   1.650208	   0.013236	  
Lan1 4.799	   2.026	   8.322	   5.049	   3.155436	   0.156316	  
Sknas 2.901	   2.685	   5.608	   3.731333	   1.628825	   0.100917	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MRP1 expression in neuroblastoma cell lines
Cell line
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Figure 33 MRP1 expression in neuroblastoma cell lines. Real time data showing SKnBe2c 
with the highest MRP1 expression in reference to UKFnb3.  
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The cell lines were then subjected to demethylation treatment by 5-aza-2'-deoxycytidin a 
demethylating agent to determine if demethylation will have an effect on MRP1 gene 
expression. 
Treatment with the demethyalting agent had no significant increase on MRP1 expression 
(Fig.24). On the other hand it caused significant decrease in MRP1 expression in 3 cell 
lines (UKFNB-4, UKFNB3-DOX, and UKFNB-3) suggesting that promoter methylation 
is not a contributing factor governing its expression. These results are consistent with 
MSP and bisulfite sequencing that showed unmethylated promoter in all 6 cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
